Navigation Links
Stem Cell Bank In UK Would Require 150 Embryo-Derived Stem Cell Lines

A results of a study conducted in Britain to project stem cell requirements for the establishment of a therapeutic stem cell bank has concluded that approximately 150 embryo-derived stem cell lines would// be required to support the functioning on a daily basis.

Britain, South Korea and the United States represent countries where intensive stem cell research is being carried out. The world's first stem cell bank was established in Britain in the year 2004. Over the next two years, the amount of resources allocated for stem cell research in UK would be doubled to 100 million pounds, a part of which would be used to support functioning of the stem cell bank.

Stem cell banks procure stem cells, store and distribute it for research purposes aimed at treatment of human diseases. This mode of treatment is called stem-cell therapy. Although the effective utilization of this form of therapy cannot be accomplished immediately, results of clinical trials conducted on animal models seem promising.

Currently, there is an increasing focus on stem cell therapy for treatment of neurodegenerative disorders (Parkinson’s disease, Alzheimer’s disease), cancer, diabetes and spinal cord injuries. Furthermore, it is estimated that a large number of stem cell lines would be required to match the recipient demand in most of the cases.

It has been estimated that a one in five recipients would have a good match if the number of potential donors were increased to 150. It would also be sufficient to provide a modest match for about 90% and an intermediate tissue match for about 50 to 70% of patients. Surprisingly, a sub-set of stem cells from 10 human embryos have been identified that could theoretically provide a very good match for about 38% of recipients.

Similar to human organ transplantation, the embryonic stem cells from a therapeutic bank would have to be tested for tissue compatibility to minimise chances of rejection
'"/>




Page: 1 2

Related medicine news :

1. Patients Pressure Would Result In Overprescription
2. Smallpox Would Spread Rapidly
3. Legalization Of Euthanasia Would Not Affect Patient’s Trus
4. UN Fears Melting Of Ice Would Concentrate Toxins in the Chinese Water Supply
5. Early Detection Of Primary Liver Cancer Would Save Millions Of Lives
6. NHS Trust Would Soon Take On The Hospital Superbug
7. 60 Million People Would Die Due To NCD In India
8. Inactivation of Rad9 in Tumor Cells Would Be Advantageous In Cancer Therapy
9. Small Cars, Anti-AIDS And Anti-Cancer Drugs Would Be Cheaper
10. Study Would Pave Way for the Development of New Drugs That Targets TB Proteasome
11. Drugs plus Awareness Would Facilitate Reduction of HIV Infection
Post Your Comments:
Other Medicine News:Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 2Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 3Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 4Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 5Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 6Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 7Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 8Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 9Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 10Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 11Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 12Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 13Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 14Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 15Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 16Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 17Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 18Health News:Rheumatoid Arthritis May Harm Gums 2Health News:Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R) 2Health News:NASA-Enhanced Dust Storm Predictions to Aid Health Community 2Health News:NASA-Enhanced Dust Storm Predictions to Aid Health Community 3
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Brain difference in psychopaths identified 9468 1Brain difference in psychopaths identified 9468 2Ferring Pharmaceuticals Announces Trade Name FIRMAGON 28R 29 28degarelix for injection 29 for Advanced Prostate Cancer Treatment 53625 1Ferring Pharmaceuticals Announces Trade Name FIRMAGON 28R 29 28degarelix for injection 29 for Advanced Prostate Cancer Treatment 53625 2Ferring Pharmaceuticals Announces Trade Name FIRMAGON 28R 29 28degarelix for injection 29 for Advanced Prostate Cancer Treatment 53625 3Ferring Pharmaceuticals Announces Trade Name FIRMAGON 28R 29 28degarelix for injection 29 for Advanced Prostate Cancer Treatment 53625 4Office of National Drug Control Policy Taps RIESTER creative for Use in National Anti Meth Campaign 53622 1Office of National Drug Control Policy Taps RIESTER creative for Use in National Anti Meth Campaign 53622 2